Article Data

  • Views 2297
  • Dowloads 128

Original Research

Open Access

The expression and significance of p-STAT3, Twist, and E-cadherin in ovarian epithelial carcinoma

  • W.S. Wang1,†
  • Y.Y. Hou1,†
  • J.Q. Hou1
  • Y.H. Chen1
  • H.Y. Jiang1
  • S.D. Chang2
  • G.Q. Wang1,*,

DOI: 10.12892/ejgo4857.2019 Vol.40,Issue 6,December 2019 pp.1019-1023

Published: 10 December 2019

*Corresponding Author(s): G.Q. Wang E-mail: cnjianqinghou@163.com

† These authors contributed equally.

PDF (135.1 kB) View Full-text

Cite and Share

W.s. Wang, Y.y. Hou, J.q. Hou, Y.h. Chen, H.y. Jiang, S.d. Chang, G.q. Wang. The expression and significance of p-STAT3, Twist, and E-cadherin in ovarian epithelial carcinoma. European Journal of Gynaecological Oncology. 2019; 40(6): 1019-1023. doi: 10.12892/ejgo4857.2019

References

[1] Tan F.H., Putoczki T.L., Stylli S.S., Luwor R.B.: “The role of STAT3 signaling in mediating tumor resistance to cancer therapy”. Curr. Drug Targets, 2014, 15, 1341.

[2] Kim M.S., Lee W.S., Jeong J., Kim S.J., Jin W.: “Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer”. Oncotarget, 2015, 6, 40158.

[3] Tobin N.P., Sims A.H., Lundgren K.L., Lehn S., Landberg G.: “Cyclin D1, Id1 and EMT in breast cancer”. BMC Can-cer, 2011, 11, 417.

[4] Loboda A., Nebozhyn M.V., Watters J.W., Buser C.A., Shaw P. M., Huang P.S., et al.: “EMT is the dominant programin human colon cancer”. BMC Med. Genomics, 2011, 4, 9.

[5] Giannelli G., Bergamini C., Fransvea E., Sgarra C., Antonaci S.: “Laminin-5 with transforming growth factor-betal induces epithelial to mesenchymal transition in hepatocellular carci-noma”. Gastroenterology, 2005, 129, 137.

[6] Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R. A., Come C., et al.: “Twist, a master regulator of morpho-

genesis, plays an essential role in tumor metastasis”. Cell, 2004, 117, 927.

[7] Christiansen J.J., Rajasekaran A.K.: “Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma in-vasion and metastasis”. Cancer Res., 2006, 66, 8319.

[8] Blechschmidt K., Sassen S., Schmalfeldt B., Schuster T., Höfler H., Becker K.F.: “The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer pa-tients”. Br. J. Cancer, 2008, 98, 489.

[9] Bhattacharya R., Kwon J., Ali B., Wang E., Patra S., Shridhar V., et al.: “Role of hedgehog signaling in ovarian cancer”. Clin. Cancer Res., 2008, 14, 7659.

[10] Yoshida J., Horiuchi A., Kikuchi N., Hayashi A., Osada R., Ohira S., Shiozawa T., et al.: “Changes in the expression of E- cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the im-portant role of Snail in ovarian tumorigenesis and progres-sion”. Med. Mol. Morphol., 2009, 42, 82.

[11] Jin H., Yu Y., Zhang T., Zhou X., Zhou J., Jia L., et al.: “Snail is critical for tumor growth and metastasis of ovarian carci-noma”. Int. J. Cancer, 2010, 126, 2102.

[12] Huang J., Zhang L., Greshock J., Colligon T.A., Wang Y., Ward R., et al.: “Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome”. Genes Chromosomes Cancer, 2011, 50, 606.

[13] Cao L., Shao M., Schilder J., Guise T., Mohammad K.S., Matei D.: “Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovar-ian cancer”. Oncogene, 2012, 31, 2521.

[14] Wang Y., Sheng Q., Spillman M.A., Behbakht K., Gu H.: “Gab2 regulates the migratory behaviors and E-cadherin ex-pression via activation of the PI3K pathway in ovarian cancer cells”. Oncogene, 2012, 31, 2512.

[15] Gao M., Wu R.C., Herlinger A.L., Yap K., Kim J.W., Wang T. L., et al.: “Identification of the NAC1-regulated genes in ovarian cancer”. Am. J. Pathol., 2014, 184, 133.

[16] Fendrich V., Waldmann J., Feldmann G., Schlosser K., König A., Ramaswamy A., et al.: “UniGue expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and maI-ignant parathyroid neopIasia”. Eur. J. Endocrinol., 2009, 160, 695.

[17] Kang Y., Massagué J.: “Epethial-mesenchymal transition: Twist in development and metastasis”. Cell, 2004, 118, 277.

[18] Ru G.Q., Wang H.J., Xu W.J., Zhao Z.S.: “UpreguIation of Twist in gastric Carcinoma associated with tumor invasion and poor prognosis”. Pathol. Oncol. Res., 2011, 17, 341.

[19] Li M., Guan H., Hu X., Wang Y., Wei Q., Yang Q.: “[Corre-lation of Twist and YB-1 up-regulation and epithelial-mes-enchymal transition during tumorigenesis and progression of cervical carcinoma]”. Zhonghua Bing Li Xue Za Zhi, 2015, 44, 594.

[20] Cao J., Wang X., Dai T., Wu Y., Zhang M., Cao R., et al.: “Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1”. Theranostics, 2018, 8, 2739.

[21] Sakowicz-Burkiewicz M., Przybyla T., Wesserling M., Bielarczyk H., Maciejewska I., Pawelczyk T.: “Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5- fluorouracil”. Int. J. Biochem. Cell Biol., 2016, 78, 268.

[22] Aleskandarany M.A., Agarwal D., Negm O.H., Ball G., El-mouna A., Ashankyty I., et al.: “The prognositic significance

of STAT3 in invasive breast cancer:analysis of protein and mRNA expression in large cohorts”. Breast Cancer Res., Treat. 2016, 156, 9.

[23] Wang Q., Cheng F., Ma T.T., Xiong H.Y., Li Z.W., Xie C.L., et al.: “Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3”. Mol. Cell. Bilchem., 2016, 415, 157.

[24] Johnston P.A., Sen M., Hua Y., Camarco D.P., Shun T.Y., Lazo J.S., et al.: “HCS campaign to identify selective in-hibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines”. Assay Drug Dev. Technol., 2015, 13, 356.

[25] Suh Y.A., Jo S.Y., Lee H.Y., Lee C.: “Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells”. Int. J. Oncol., 2015, 46, 1405.

[26] Jung I.H., Choi J.H., Chung Y.Y., Lim G.L., Park Y.N., Park

S. W.: “Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis”. Neo-plasia, 2015, 17, 586.

[27] Kim M.S., Lee W.S., Jeong J., Kim S.J., Jin W.: “Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer”. Oncotar-get, 2015, 6, 40158.

[28] Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al.: “Interleukin-6 induces an epithelial-mes-enchymal transition phenotype in human breast cancer cells”. Oncogene, 2009, 28, 2940.

[29] Hsu K.W., Hsieh R.H., Huang K.H., Fen-Yau Li A., Chi

C. W., Wang T.Y., et al.: “Activation of the Notchl/STAT3/Twist signaling axis promotes gastric cancer progression”. Carcinogenesis, 2012, 33, 1459.

[30] Zhang C.H., Xu G.L., Jia W.D., Li J.S., Ma J.L., Ren W.H., et al.: “Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance”. J. Surg. Res., 2012, 174, 120.

Submission Turnaround Time

Top